<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133573</url>
  </required_header>
  <id_info>
    <org_study_id>13-010710</org_study_id>
    <nct_id>NCT02133573</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Maternal Progesterone Therapy</brief_title>
  <official_title>Randomized Trial of Maternal Progesterone Therapy to Improve Neurodevelopmental Outcomes in Infants With Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurodevelopmental disability is now recognized as the most common long-term complication
      after cardiac surgery in neonates. Research studies have shown that progesterone is critical
      to the development of the brain and in a variety of clinical situations including brain
      injury can protect the brain.

      The purpose of this research study is to determine whether progesterone administered during
      the 3rd trimester of pregnancy (24-39 weeks) to pregnant women protects the brain of unborn
      babies with CHD and improves their neurodevelopmental outcomes after heart surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the United States, approximately 1 in every 100 newborns is diagnosed with congenital
      heart disease (CHD). Many of these newborns (25%-35%) will require either corrective or
      palliative open heart surgery. As recently as the 1960's, only 20% of newborns with critical
      CHD survived to adulthood. Today, thanks to better diagnostic technologies and methods
      (including prenatal diagnosis), advances in surgery, and improved postoperative care, early
      survival is over 90%. However, with improved early outcomes has come the sobering recognition
      that there is an ongoing risk of late mortality, as well as significant morbidity for these
      children. In particular, neurodevelopmental disability is now recognized as the most common
      complication of critical CHD (i.e. those patients requiring cardiac surgery in infancy) and
      has the most negative impact on quality of life, academic performance and opportunity for
      independence as an adult.

      The altered fetal hemodynamics secondary to CHD lead to decreased blood flow and/or oxygen
      delivery to the fetal brain. In turn, this impairment in blood flow and oxygenation results
      in impaired brain growth and altered structural and cellular maturation, particularly of the
      white matter. Fetal MRI studies have shown that during the third trimester, normally a time
      of rapid brain growth and development, brains of infants with CHD fail to grow at the same
      rate as the brains of fetuses without CHD. This growth delay results in microcephaly,
      immature cellular elements of the white matter and decreased cortical folding at birth. It
      has been demonstrated that brain immaturity at birth is a primary major risk factor
      underlying the hypoxic-ischemic white matter brain injury and subsequent neurodevelopmental
      disability seen in over 50% of infants following surgery for CHD. In addition, there is
      increasing evidence in the CHD population that even late pre-term birth (prior to 39 weeks
      GA) is associated with increased mortality, increased peri-operative morbidity, and worse
      neurodevelopmental outcomes.

      Progesterone is an essential hormone in the occurrence and maintenance of pregnancy.
      Progesterone administration has also been shown to be neuroprotective in a variety of
      clinical situations, including traumatic brain injury (TBI). Sex steroid hormones, including
      progesterone, are critically involved in axonal myelination, forming the basis of white
      matter connectivity in the central nervous system (CNS). Progesterone and its metabolites not
      only promote the viability and regeneration of neurons, but also act on myelinating glial
      cell oligodendrocytes in the CNS and play an important role in the formation of myelin
      sheaths. Progesterone has also been shown to increase myelination and enhance maturation of
      immature oligodendrocytes progenitor cells to mature oligodendrocytes, which are more
      resistant to hypoxic/ischemic injury. Therapeutic administration of progesterone has also
      been demonstrated to prevent preterm birth. Thus, there are two potential mechanisms by which
      pre-natal progesterone therapy may improve neurodevelopmental outcomes in neonates with CHD:
      1) a direct neuroprotective effect, and 2) decreasing the occurrence of pre-term birth.

      Study Objectives

      Primary: Develop preliminary evidence to support a multi-institutional study to determine
      whether, in women carrying fetuses (maternal-fetal dyad) with CHD, prophylactic vaginal
      natural progesterone therapy is neuroprotective, and compared to placebo improves
      neurodevelopmental outcomes at 18 months of age.

      Secondary: Develop preliminary evidence to support a multi-institutional study to determine
      whether, in women carrying fetuses (maternal-fetal dyad) with CHD, prophylactic vaginal
      natural progesterone therapy is neuroprotective, and compared to placebo:

        1. improves fetal brain growth and maturation,

        2. increases myelination during fetal brain development,

        3. reduces pre-operative brain white matter injury, and

        4. reduces post-operative white matter injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor Scale of the Bayley Scales of Infant and Toddler Development-III</measure>
    <time_frame>When baby is 18 months of age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive and Language Scales of the Bayley Scale of Infant and Toddler Development-III</measure>
    <time_frame>When baby is 18 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal brain growth and maturation by MRI</measure>
    <time_frame>Change from 24-28 weeks gestational age to 34-36 weeks gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myelination during fetal brain development by MRI</measure>
    <time_frame>Change from 24-28 weeks gestational age to 34-36 weeks gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain white matter injury by MRI</measure>
    <time_frame>Preoperative on day of surgery</time_frame>
    <description>Heart surgery with cardiopulmonary bypass (CPB) prior to 44 weeks corrected gestational age (GA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain white matter injury by MRI</measure>
    <time_frame>Postoperative within 10 days of surgery</time_frame>
    <description>Heart surgery with cardiopulmonary bypass (CPB) prior to 44 weeks corrected gestational age (GA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Periventricular Leucomalacia</condition>
  <condition>Brain Development</condition>
  <condition>Cardiac Surgery</condition>
  <condition>Neurodevelopmental Disability</condition>
  <condition>Fetal Neuroprotection</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaginal gel, 90mg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Lubricant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vaginal twice a day (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.</description>
    <arm_group_label>Progesterone</arm_group_label>
    <other_name>Crinone 8%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal lubricant</intervention_name>
    <description>Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.</description>
    <arm_group_label>Vaginal Lubricant</arm_group_label>
    <other_name>Replens</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Mother carrying a fetus with CHD (maternal-fetal dyad) requiring
        surgery with cardiopulmonary bypass (CPB) prior to 44 weeks corrected gestational age (GA)
        identified prior to 28 weeks GA.

        Exclusion Criteria:

          1. Major genetic or extra-cardiac anomaly other than 22q11 deletion

          2. Language other than English spoken in the home

          3. Known sensitivity or listed contraindication to progesterone (known allergy or
             hypersensitivity to progesterone, severe hepatic dysfunction, undiagnosed vaginal
             bleeding, mammary or genital tract carcinoma, thrombophlebitis, thromboembolic
             disorders, cerebral hemorrhage, porphyria)

          4. Prescription or ingestion of medications known to interact with progesterone (e.g.
             Bromocriptine, Rifamycin, Ketoconazole or Cyclosporin)

          5. Maternal use of progesterone within 30 days of enrollment

          6. History of preterm birth or short cervix (defined as cervical length â‰¤ 25 mm at 18-24
             weeks GA necessitating progesterone therapy

          7. Multiple gestation

          8. Maternal contraindication for magnetic resonance imaging (MRI)

          9. Subjects with a known history of non-compliance with medical therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. William Gaynor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin E Zullo, BSN</last_name>
    <phone>215-360-8615</phone>
    <email>wehrunge1@email.chop.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Burnham, MSN</last_name>
      <phone>215-410-0721</phone>
      <email>burnhamn@email.chop.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.chop.edu/service/fetal-diagnosis-and-treatment/the-center-for-fetal-research/fetal-neuroprotection-neuroplasticity.html</url>
    <description>The Children's Hospital of Philadelphia Fetal Neuroprotection and Neuroplasticity Program</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progesterone</keyword>
  <keyword>congenital heart disease</keyword>
  <keyword>periventricular leucomalacia</keyword>
  <keyword>brain development</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>neurodevelopmental disability</keyword>
  <keyword>fetus</keyword>
  <keyword>fetal neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Leukomalacia, Periventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

